SHJBF:OTC-Shanghai Junshi Biosciences Co. Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.97

Change

0.00 (0.00)%

Market Cap

USD 3.41B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 42.54B
GNMSF Genmab A/S

+4.22 (+2.11%)

USD 12.13B
IVBIY IVBIY

N/A

USD 10.52B
WXXWY WuXi Biologics (Cayman) Inc

+0.03 (+0.52%)

USD 10.47B
WXIBF WuXi Biologics

N/A

USD 10.43B
AKESF Akeso, Inc.

-1.94 (-14.28%)

USD 9.51B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 9.09B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 9.09B
TLPPF Telix Pharmaceuticals Limited

-2.25 (-11.68%)

USD 5.56B
ZLDPF Zealand Pharma A/S

N/A

USD 4.46B

ETFs Containing SHJBF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 5.91% 67% D+ 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.91% 67% D+ 59% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -33.83% 15% F 6% D-
Dividend Return -33.83% 15% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.75% 90% A- 79% B-
Risk Adjusted Return -136.71% 4% F 2% F
Market Capitalization 3.41B 96% N/A 83% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector